<DOC>
	<DOCNO>NCT02505750</DOCNO>
	<brief_summary>The investigator propose conduct randomise study cT2 , cT3a-b tumour le 5 cm use two different technique radiotherapy boost follow neoadjuvant chemoradiotherapy ( nCRT ) ( CAP45 ) : EBRT ( 9 Gy/5 fraction ) CXB ( 90 Gy/3 fraction ) . The endpoint organ preservation 3 year without non-salvageable local pelvic recurrence . The proof concept benefit patient especially elderly usually fit keen undergo major surgery . The hypothesis study determine whether addition endocavitary boost CXB standard treatment nCRT , increase chance rectum anus preservation 20 % -unites early rectal adenocarcinoma without locally progressive disease ( organ preservation control arm 20 % , experimental arm 40 % ) . Main objective To demonstrate neoadjuvant chemoradiotherapy combination boost give CXB ( Arm B ) superior neoadjuvant therapy plus boost EBRT alone ( Arm A ) term rectum ( organ ) preservation without non salvageable local disease 3 year post treatment start , permanent deviate stoma . Study Design Open-label , phase III , prospective , multi-centre , international , randomise 1:1 , 2 arm study design evaluate efficacy CXB boost versus EBRT boost .</brief_summary>
	<brief_title>Safety Boost ( CXB EBRT ) Combination With Neoadjuvant Chemoradiotherapy Early Rectal Adenocarcinoma</brief_title>
	<detailed_description>Rationale - current state knowledge Current guideline cT2-T3 ( clinical stage T2 T3 ) low middle rectal cancer recommend radical total mesorectal excision ( TME ) surgery may involve permanent stoma low anterior resection sometimes poor bowel function . Randomised trial show neoadjuvant ( chemo ) radiotherapy ( nCRT ) reduce risk local recurrence half . At 3 year , close 5 % acceptable toxicity many center . On hand , provide definite improvement overall survival increase chance conservative surgery . Rectal adenocarcinoma rather radioresistant dose require achieve 50 % sterilization close 90 gray ( Gy ) , high dose cause toxicity give external beam radiation therapy ( EBRT ) . Among radiotherapy technique able achieve safely high dose , Contact X-Ray Brachytherapy 50 Kv ( CXB ) appeal method . The Lyon R96-2 randomise trial use CXB show increased clinical complete response ( cCR ) rate 2 % 29 % improvement 30 % chance avoid permanent stoma ( 72 % vs. 42 % ) . In addition , patient achieve cCR able preserve sphincter whole rectum ( organ preservation ) either local excision use `` watch wait '' strategy . Such conservative approach receive grow interest world among colorectal cancer specialist . The extensive pioneering work Prof. Habr Gama Brazil presently consider reference use chemoradiotherapy EBRT boost ( total dose 54 Gy/30 f/6 week ) follow watch wait case cCR preserve organ , i.E . avoid surgery . Research Hypothesis The investigator propose conduct randomise study cT2 , cT3a-b tumour le 5 cm use two different technique radiotherapy boost follow neoadjuvant chemoradiotherapy ( nCRT ) ( CAP45 ) : EBRT ( 9 Gy/5 fraction ) CXB ( 90 Gy/3 fraction ) . The endpoint organ preservation 3 year without non-salvageable local pelvic recurrence . The proof concept benefit patient especially elderly usually fit keen undergo major surgery . The hypothesis study determine whether addition endocavitary boost CXB standard treatment nCRT , increase chance rectum anus preservation 20 % -unites early rectal adenocarcinoma without locally progressive disease ( organ preservation control arm 20 % , experimental arm 40 % ) . Main objective To demonstrate neoadjuvant chemoradiotherapy combination boost give CXB ( Arm B ) superior neoadjuvant therapy plus boost EBRT alone ( Arm A ) term rectum ( organ ) preservation without non salvageable local disease 3 year post treatment start , permanent deviate stoma . Study Design Open-label , phase III , prospective , multi-centre , international , randomise 1:1 , 2 arm study design evaluate efficacy CXB boost versus EBRT boost . Randomisation : Arm A : 3D conformal EBRT 45 Gy ( 1.8 Gy/fraction/5 week ) concurrent chemotherapy use capecitabine ( 825 mg/m2 bid , radiation day ) . A cone EBRT target Gross Tumour Volume ( GTV ) deliver boost dose 9 Gy 5 fraction . On week 14 start treatment , tumour response evaluation guide final strategy : surgery ( radical TME local excision ) watch-and-wait ( W-W ) . Arm B divide 2 subgroup depend tumour diameter : B1 : If tumour &lt; 3 cm , CXB boost dose ( 90Gy/3 fractions/4 week ) initially deliver tumour . After 2 week rest , patient receive 3D conformal EBRT 45 Gy ( 1.8 Gy/fraction/5 week ) concurrent chemotherapy use capecitabine ( 825 mg/m2 bid , radiation day ) . Clinical evaluation perform 3 week end irradiation ( week 14 ) guide final strategy ( surgery W-W ) arm A. B2 : If tumour ≥ 3 cm , patient receive EBRT first 45 Gy ( 1.8 Gy/fraction/5 week ) concurrent chemotherapy use capecitabine ( 825 mg/m2 bid , radiation day ) . A CXB boost dose ( 90 Gy/3 fractions/4 week ) deliver residual tumour , rest 2 week . On week 14 start treatment , tumour response evaluation guide final strategy ( surgery W-W ) arm A . Adjuvant chemotherapy leave institution choice . Number subject : Taking alpha=5 % bêta=7.5 % 10 % patient evaluable randomisation , 236 patient ( 118 patients/arm ) must enrol show 50 % increase main endpoint 3 year ( 20 % 40 % ) .This study show hazard ratio 0.56 . Stopping rule : non-salvageable local recurrence rate &gt; 10 % checked independent Data Monitoring Committee every 80 patient .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Adenocarcinoma rectum classify clinically T2 , T3a , T3b ( penetration mesorectal fat 1 5 mm ) TNM classification ( Tumour Node Metastase ) , &lt; 5 cm large diameter , &lt; half rectal circumference ( MRI stag ) , N0N1 ( node &lt; 8 mm diameter MRI ) , M0 2 . Operable patient 3 . Tumour accessible endocavitary contact XRay Brachytherapy distance low tumour border anal verge ≤ 10cm 4 . 18 year 5 . No comorbidity prevent treatment 6 . Adequate birth control 7 . Patient read information note sign informed consent 8 . Health care insurance available 9 . Followup possible 1 . Inoperable patient 2 . T1 , T3cd , T4 , T≥ 5cm , T≥ ½ circumference 3 . Patient N2 diagnosis N1 node &gt; 8 mm diameter 4 . Patient present metastasis diagnosis 5 . Previous pelvic irradiation 6 . Tumour extramural vascular invasion 7 . Simultaneous progressive cancer 8 . Tumour invade external anal sphincter within 1 mm , levator muscle 9 . Patient unable receive CXB CRT 10 . Tumour poor differentiation ( G3 ) 11 . People particularly vulnerable define Articles L.11215 8 French Healthcare Code , include : person deprive freedom administrative judicial decision , adult object legal protection measure outside state express consent , pregnant breastfeed woman 12 . Any significant concurrent medical illness opinion investigator would preclude protocol therapy 13 . Patient history poor compliance current past psychiatric condition severe acute chronic medical condition would interfere ability comply study protocol 14 . Concurrent enrolment another clinical trial use investigational anticancer treatment within 28 day prior first dose study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>